Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy-Reference-Cited by-同舟云学术

Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy

Published:2022-03-30 Issue:3 Volume:49 Page:425-432
ISSN:1346-4523
Container-title:Journal of Medical Ultrasonics
language:en
Short-container-title:J Med Ultrasonics

Author:

Matsumoto Naoki^ORCID,Ogawa Masahiro,Kaneko Masahiro,Arima Shuhei,Kumagawa Mariko,Watanabe Yukinobu,Hirayama Midori,Masuzaki Ryota,Kanda Tatsuo,Moriyama Mitsuhiko

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10396-022-01204-8.pdf

Reference26 articles.

1. Kudo M, Izumi N, Sakamoto M, Liver Cancer Study Group of Japan, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016;5:190–7.

2. Zschäbitz S, Grüllich C, Lenvantinib A. Tyrosine kinase inhibitor of VEGFR-3, FGFR 1–4, PDGFRα, KIT and RET. Recent Results Cancer Res. 2018;211:187–98.

3. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

4. Hiraoka A, Kumada T, Kariyama K, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111–7.

5. Kunimoto H, Shakado S, Tanaka T, et al. Reduction in tumor stain at 2 weeks after treatment initiation is a predictor of the efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma. Oncology. 2020;98:779–86.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy;Ultrasound in Medicine & Biology;2024-01

2. Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma;Magnetic Resonance in Medical Sciences;2023

3. Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma;Oncology;2022-12-14